AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 141 min read$CRBP

Corbus Announces Positive Phase 1b Weight-Loss Data Showing For Oral Candidate CRB-913; Stock Up

Corbus Pharmaceuticals (CRBP) reported positive Phase 1b trial results for CRB-913, showing 5% mean weight loss at 12 weeks. The drug was well-tolerated, with no plateau in weight reduction. The company plans Phase 2 development, aiming to start a monotherapy study in early 2027. CRBP stock rose 20.07% in pre-market trading.

Original reporting
rttnews.com
Published Sep 14, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 4:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$CRBP
Bullish
high confidence
Mentioned
$CRBP
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$CRBPBullishHigh
01

Why it matters

The 5% weight loss at 12 weeks positions CRBP as a differentiated oral candidate, likely attracting partnership interest.

02

Market read

First‑time positive trial data can drive short‑term price appreciation and longer‑term valuation uplift.

03

What to watch

Potential regulatory hurdles and competition from established GLP‑1 injectables.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Corbus Pharmaceuticals focuses on peripheral CB1 inverse agonists for obesity, a market dominated by GLP‑1 injectables.

Company-level read

Ticker impact

$CRBPBullishHigh confidence
Context

Positive Phase 1b obesity data for CRB-913 released, stock up 20% pre‑market.

Expected impact

Expect continued upside as investors price in Phase 2 initiation.

Evidence & confidence

First disclosure of statistically significant 5% weight loss; no prior public data.

Market effects

Sector

May spur interest in peripheral CB1 antagonists across obesity biotech space.

Regional

US biotech sector could see modest lift.

Global

Obesity treatment market globally gains a potential new oral option.

Counterpoint

What could challenge this read

Phase 1b data are early; efficacy and safety still unproven at later stages.

Key entities

  • company
    Corbus Pharmaceuticals Holdings, Inc.

    Developer of CRB-913, a peripheral CB1 inverse agonist.

  • executive
    Yuval Cohen, Ph.D.

    CEO of Corbus, quoted on trial results.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 15
$CRBPMedAI 9/10

Corbus Obesity Pill Shows 5% Weight Loss With Clean Safety Profile in Mid-Stage Trial — BigGo Finance

Corbus Pharmaceuticals' (CRBP) obesity pill, CRB-913, achieved 5% weight loss in a 12-week mid-stage trial with no serious psychiatric side effects, positioning it for Phase 2 testing. The drug showed dose-dependent weight loss and a favorable safety profile compared to earlier CB1 inverse agonists. Corbus plans to discuss Phase 2 trial plans with the FDA. Shares have risen 342% year-to-date.

finance.biggo.com2 min
SEP 15
$CRBPMedAI 8/10

Obesity drug could have fewer side effects than GLP-1s

Corbus Pharmaceuticals reported that its obesity drug, CRB-913, achieved 5% weight loss at 60mg after 12 weeks, with fewer gastrointestinal side effects than GLP-1 drugs, according to the company. The drug targets CB1 receptors to reduce hunger signals, with psychiatric side effects similar to GLP-1s, but minimal brain penetration. The company claims it may preserve muscle mass better than GLP-1s. The rise of obesity drugs is reshaping consumer food choices, regardless of future drug development

foodnavigator.com2 min
SEP 14
$CRBPHighAI 8/10

Why is Corbus Pharmaceuticals stock surging today?

Corbus Pharmaceuticals (CRBP) stock rose 14.4% pre-market after reporting positive Phase 1b trial results for its obesity drug CRB-913, showing significant weight loss and a favorable safety profile. The company plans to present full data in November and initiate a Phase 2 study in 2027. The stock had been near its 52-week low before the announcement.

investing.com2 min
SEP 14
$CRBPHighAI 9/10

Corbus Pharmaceuticals stock rises on obesity drug trial data

Corbus Pharmaceuticals (CRBP) shares rose 12% after reporting positive Phase 1b trial data for obesity drug CRB-913. The 60 mg dose showed 5% mean weight loss at 12 weeks. The trial enrolled 254 participants and tested three doses, all showing significant weight loss. The drug was generally well tolerated. Corbus plans to discuss further development with the FDA and start a Phase 2 study in early 2027.

investing.com2 min
SEP 14
$CRBPMedAI 9/10

Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Corbus Pharmaceuticals Announces Positive Topline Data from CANYON-1 Study of Daily Oral CRB-913 for the Treatment of Obesity • CRB-913 demonstrated statistically significant and clinically meaningful mean weight loss of 5% at 60 mg after 12 weeks with no plateau obs

SEC EDGAR 8-K2 min
AUG 6
$CRBPMed

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals Holdings, Inc. (CRBP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update • Obtained FDA clearance to proceed with registrational study (TEMPO-1) of CRB-701 in 2L oropharyngeal cancer and expect to initiate enrollment in September 2026 • Concluded last

SEC EDGAR 8-K5 min